02096nas a2200373   4500000000100000008004100001653001100042653001500053653001400068653003200082653000900114653001900123653002200142653002000164653001100184653001800195653001600213653002200229653001100251653003600262653001000298653001900308653002200327653002500349653001200374653001000386100001400396245008700410856008000497300000700577490000700584520111700591022001401708       2014                            d10aTravel10aPrevalence10aPregnancy10aPostoperative Complications10aMale10aInsect Vectors10aInfection Control10aInfant, Newborn10aHumans10aGlobal health10aForecasting10aFood Parasitology10aFemale10aCommunicable Diseases, Emerging10aChild10aChagas disease10aBlood Transfusion10aAntiprotozoal Agents10aAnimals10aAdult1 aBonney KM00aChagas disease in the 21st century: a public health success or an emerging threat?  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952655/pdf/parasite-21-11.pdf  a110 v213 a<p>Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, is a major public health burden in Latin America and a potentially serious emerging threat to a number of countries throughout the world. Although public health programs have significantly reduced the prevalence of Chagas disease in Latin America in recent decades, the number of infections in the United States and non-endemic countries in Europe and the Western Pacific Region continues to rise. Moreover, there is still no vaccine or highly effective cure available for the approximately 10 million people currently infected with T. cruzi, a third of which will develop potentially fatal cardiomyopathy and/or severe digestive tract disorders. As Chagas disease becomes an increasingly globalized public health issue in the twenty-first century, continued attentiveness from governmental and health organizations as well as improved diagnostic tools, expanded surveillance and increased research funding will be required to maintain existing public health successes and stymie the spread of the disease to new areas and populations.</p>
  a1776-1042